Podcast: US FDA’s ‘Within Label’ Definition Allows Companies To Elaborate On Indications
Permitted speech for approved products could shift dramatically depending on how hard a Trump FDA Commissioner pushes, but the expansion at the end of the Obama Administration is a significant step in its own right – one that former Commissioner Rob Califf emphasizes in an interview that is also available as a podcast.
You may also be interested in...
Uncertainty about US FDA's direction under the new president may have spurred staff to ensure views on several issues released before administration changed.
US FDA draft guidance offers three-factor test to determine when communication about a medical product is consistent with labeling; information on patient-reported outcomes and mechanism of action are okay.
FDA is joining the government’s bioresponse and defense efforts to develop small, mobile, on-demand manufacturing systems as next-tech solutions to dwindling domestic supply sources for essential drugs.